Cancer treatment as a non-traditional risk factor for atherosclerosis

Authors: Pavel Kraml 1,2,3
Authors‘ workplace: Centrum pro výzkum diabetu, metabolismu a výživy 3. LF UK a FN Královské Vinohrady, Praha 1;  Centrum pro diagnostiku a léčbu hyperlipoproteinemií 3. LF UK a FN Královské Vinohrady, Praha 2;  Interní klinika 3. LF UK a FN Královské Vinohrady, Praha 3
Published in: AtheroRev 2022; 7(2): 76-81
Category: Reviews


The prognosis of patients with oncological diseases is significantly improving due to the modern therapeutic options. More and more patients achieve remission, however their cardiovascular risk is increasing. In fact, all types of oncology treatment (radiotherapy, chemotherapy, hormonal therapy, biological therapy, stem cell transplant) may accelerate atherosclerosis, either by their toxic effect on arterial endothelium or through oxidative stress, proinflammatory state and insulin resistance. For cardiovascular risk assessment in these patients we have to evaluate not only the traditional risk factors but also the impact of oncological treatment, which can be difficult in some therapeutics, especially the modern ones with not sufficient data available. During the oncological therapy as well as in remission, patients with preexisting cardiovascular disease or those with cumulation of traditional risk factors should be observed by team of specialists involving both oncologists and cardiologists. However, definite and unanimous guidelines reflecting type of the oncology disease, the length and intensity of each therapeutic modality, the age of the patient or duration of remission are still lacking, both for the secondary as well as the primary prevention of atherosclerotic cardiovascular diseases (ASCVD).


Atherosclerosis – cardiovascular risk – cardio-oncology – oncology therapy


1. Sturgeon KM, Deng L, Bleuthmann SM. A population- based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019; 40: 3889–3897. Dostupné z DOI: <htpps://>.

2. Aleman BM, Moser EC, Nuver J et al. Cardiovascular disease after cancer therapy. EJC Suppl 2014; 12(1): 18–28. Dostupné z DOI: <htpps://>.

3. Roubín SR, Cordero A. The Two-way Relatinship Between Cancer and Atherosclerosis. Rev Esp Cardiol 2019; 72(6): 487–494. Dostupné z DOI: <htpps://>.

4. García AM, Mitroi C, Ramos PM et al. Stratifcation and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR SEHH, SEMG, AEEMT, AEEC, and AECC. Rev Esp Cardiol 2021; 74(5): 438–448. Dostupné z DOI: <htpps:// >.

5. Simonetto C, Mayinger M, Ahmed T et al. Longitudinal atherosclerotic changes after radio(chemo)therapy of hypopharyngeal carcinoma. Radiation Oncology 2020; 15(102): 1–6. Dostupné z DOI: <htpps://>.

6. Zheng HC, Onderko L, Francis SA. Cardiovascular risk in survivors of cancer. Curr Cardiol Rep 2017; 19: 64. Dostupné z DOI: <–017–0873–7>.

7. Yang EH, Marmagkiolis K, Balanescu DV et al. Radiation-Induced Vascular Disease-A State-of-the-Art Review. Front. Cardiovasc Med 2018;

8. Dostupné z DOI: <>.

8. Yeh ET, Bickford CL. Cardiovascular Complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 2009; 53(24):2231–2247. Dostupné z DOI: <http://doi: 10.1016/j.jacc.2009.02.050>.

9. Soultati A, Mountzios G, Avgerinou C et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012; 38(5): b473–83. Dostupné z DOI: <http://doi:10.1016/j.ctrv.2011.09.002>.

10. Minotti G, Menna P, Salvatorelli E at al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56(2): 185–229. Dostupné z DOI: <http://doi: 10.1124/pr.56.2.6>.

11. Lechner D, Kollars M, Gleiss A et al. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007; 5(12): 2445–2452. Dostupné z DOI: <http://doi: 10.1111/j.1538–7836.2007.02788.x>.

12. Nuver J, Smit AJ, Sleifer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40(5): 701–706. Dostupné z DOI: <http://doi: 10.1016/j.ejca.2003.12.012>.

13. Vaughn DJ, Palmer SC, Carver JR et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112(9): 1949–1953. Dostupné z DOI: <http://doi: 10.1002/cncr.23389>.

14. Morbidelli L, Donnini S, Ziche M. Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents. Cardiooncology 2016; 2(1): 3. Dostupné z DOI: <–016–0010–6>.

15. Wood SC, Tang X, Tesfamariam B. Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells. J Cardiovasc Pharmacol 2010; 55(3): 276–285. Dostupné z DOI: <>.

16. Damrongwatanasuk R, Fradley MG. Cardiovascular complications of targeted therapies for chronic myeloid leukemia. Curr Treat Options Cardiovasc Med 2017; 19: 24. Dostupné z DOI:–017–0524–8.

17. Pun SC, Neilan TG. Cardiovascular side effects of small molecule therapies for cancer. Eur Heart J 2016; 37: 2742–2745. Dostupné z DOI: <>.

18. Chen F, Loscalzo J. Cardiotoxicity of Cancer Immunotherapy. Trends Immunol 2017; 38(2): 77–78. Dostupné z DOI: <>.

19. Matthews A, Stanway S, Farmer RE et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ 2018; 363: k3845. Dostupné z DOI: <>.

20. Hu JR, Duncan MS, Morgans AK et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol 2020; 40: e55-e64. Dostupné z DOI: <>.

21. Huang X, Maguire OA, Walker JM et al. Therapeutic radiation exposure of the abdomen during childhood induces chronic adipose tissue dysfunction. JCI Insight 2021; 6(21): e153586. Dostupné z DOI: <http://dx.doi.or10.1172/jci.insight.153586>.

22. Westerink MDNL, Nuver J, Lefrandt J et al. Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Critical Reviews in Oncology/Hematology 2016; 108: 128–136. Dostupné z DOI: <>.

23. Chow EJ, Mueller BA, Baker KS et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011; 155: 21–32. Dostupné z DOI: <–4819–155–1-201107050–00004>.

24. Cepelova M, Kruseova J, Luks A et al. Accelerated atherosclerosis, hyperlipoproteinemia and insulin resistance in long-term survivors of Hodgkin lymphoma during childhood and adolescence. Neoplasma 2019; 66(6): 978–987. Dostupné z DOI: http://doi 10.4149/neo_2019_190115N45.

25. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37(29): 2315–2381. Dostupé z DOI: <>.

26. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42: 2439–2454. Dostupné na DOI: <htpps://>.

27. Zamorano JL, Lancellotti P, Munoz DR. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developer under the auspices of the ESC Committee for Practice Guideines: The Task Force for cancer tratments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(16): 2768–2801. Dostupné z DOI: <>.

28. Armenian SH, Xu L, Ky B et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol 2016; 34(10): 1122–1130. Dostupné z DOI: <htpps://>.

29. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <htpps://>.

30. Quagliar V, Buccolo S, Iovine M et al. PCSK9 inhibitor evolocumab to increase anticancer activities and reduce cardiotoxicity during doxorubicin and trastuzumab, as sequential treatment, through MyD88/NF-kB/mTORC1 pathways. Journal of Clinical Oncology 2021; 39(15 suppl): e15039-e15039. Dostupné z DOI: <htpps://>.

Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account